Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810.
Leonard J ApplemanSe Eun KimWayne B HarrisSumanta Kumar PalMichael R PinsJill M KolesarArchana M AgarwalRahul A ParikhDaniel A VaenaChristopher W RyanMehmood HashmiBrian A CostelloDavid CellaJanice P DutcherRobert S DiPaolaNaomi B HaasLynne I WagnerMichael A CarducciPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Pazopanib did not improve DFS as the primary end point compared with blinded placebo in patients with mRCC with NED after metastasectomy. In addition, there was a concerning trend favoring placebo in OS.